InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,354.03
(
1.18%
)
US TECH 100
18,555.60
(
2.10%
)
Dow Jones
38,807.33
(
0.25%
)
Brent Oil
78.70
(
0.17%
)
Bitcoin
70,915.88
(
-0.23%
)
Post# of 177
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1743
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: None

Tuesday, 12/14/2010 10:28:33 AM

Tuesday, December 14, 2010 10:28:33 AM

Post# of 177
Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C

I personally like everything about this trial. Though Pharmasset is focusing on the easiest to treat patients (treatment naive Genotype 2/3) they are the first company to run a interferon free single agent trial in combination with ribavirin. It's a bold statement that no other HCV company can match.



http://investor.pharmasset.com/releasedetail.cfm?ReleaseID=536627
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up